Skip to main content

Table 2 Matched-pair analysis for binominal variables

From: Matched-pair analysis: identification of factors with independent influence on the development of PTLD after kidney or liver transplantation

Variables (+)/(−)a

Nr. of analyzed matched pairs in %

Concordant pairs

Discordant pairs

p valueb

Combination PTLD (+) and non-PTLD (+)

Combination PTLD (−) and non-PTLD (−)

Combination PTLD (−) and non-PTLD (+)

Combination PTLD (+) and non-PTLD (−)

Death

100.0

2

22

1

11

0.004

Subsequent re-transplants

100.0

1

26

5

4

0.739

Living Donor

100.0

4

18

5

9

0.285

BMI >30 kg/m2

100.0

0

32

2

1

0.564

Diabetes

100.0

0

32

2

2

1.000

Alcohol abuse

100.0

0

34

2

0

n.d.

Active Smoking

100.0

0

31

2

3

0.655

COPD

100.0

0

35

1

0

n.d.

Recipient EBV IgG at Tx

86.1

12

13

4

2

0.414

Recipient CMV IgG at Tx

91.7

9

15

6

3

0.317

Donor CMV IgG at Tx

97.2

13

8

5

9

0.285

Recipient Anti-HCV at Tx

61.1

0

22

0

0

n.d.

Anti-CMV treatment after Tx

100.0

10

9

7

10

0.467

Ganciclovir/valganciclovir after Tx

100.0

9

11

7

9

0.617

Pre-transplant malignancy

100.0

2

34

0

0

1.000

Pre-transplant HCC

100.0

2

34

0

0

1.000

Non-PTLD malignancy after Tx

100.0

0

31

2

3

0.655

Breast cancer after Tx

100.0

0

35

0

1

n.d.

Pre-transplant dialysis

100.0

12

20

2

2

1.000

Donor HLA A26, B38

75.0

0

25

0

2

n.d.

Donor HLA A1

75.0

1

15

5

6

0.763

Donor HLA B8

75.0

1

21

3

2

0.655

Donor HLA DR3

75.0

1

20

4

2

0.414

Recipient HLA A26, B38

52.8

0

18

0

1

n.d.

Recipient HLA A2

52.8

6

2

10

1

0.007

Recipient HLA A11

52.8

0

15

3

1

0.317

Recipient HLA B5

52.8

0

15

2

2

1.000

Recipient HLA B18

52.8

0

16

3

0

n.d.

Recipient HLA B21

52.8

0

18

1

0

n.d.

Recipient HLA B35

52.8

1

12

4

2

0.414

Recipient HLA A3

52.8

1

10

4

4

1.000

Recipient HLA DR27

52.8

0

19

0

0

n.d.

HLA A locus mismatching

47.2

7

2

3

5

0.480

HLA B locus mismatching

47.2

10

0

3

4

0.706

HLA DR locus mismatching

47.2

12

2

2

1

0.564

Anti-thymocyte globulin after Tx

86.1

0

30

1

0

n.d.

Basiliximab therapy after Tx

86.1

6

11

7

7

1.000

Daclizumab therapy after Tx

86.1

0

29

1

1

1.000

Tacrolimusc after Tx

100.0

5

18

3

10

0.052

Ciclosporinec after Tx

100.0

17

5

10

4

0.109

MMFc after Tx

100.0

10

15

5

6

0.763

Myforticc after Tx

100.0

0

35

0

1

n.d.

Steroidsc after Tx

100.0

32

1

1

2

0.564

Sirolimusc after Tx

100.0

0

34

1

1

1.000

Everolimusc after Tx

100.0

0

34

1

1

1.000

Azathioprinc after Tx

100.0

1

33

2

0

0.157

Tacrolimus at PTLDd

100.0

7

14

6

9

0.439

Ciclosporine at PTLDd

100.0

12

12

9

3

0.083

CNI-free treatment at PTLDd

100.0

1

30

1

4

0.180

  1. Summarized are the results of matched-pair analysis for binominal variables. Their distribution in concordant and discordant pairs in matched-pair analysis is shown
  2. a(+)/(−)-classifiers identify yes/no or positive/negative variables
  3. bMcNemar’s test for binary variables
  4. cAt hospital discharge
  5. dDiagnosis or equivalent date in the non-PTLD group
  6. Tx transplantation, COPD chronic obstructive pulmonary disease, BMI body mass index, EBV Epstein-Barr virus, CMV cytomegalovirus, HCC hepatocellular carcinoma, HCV hepatits C virus, HLA human leukocyte antigen, MMF mycophenolat mofetil, CNI calcineurin inhibitor, n.d. p value not determined due to zero cases within pairs (McNemar’s test)
Back to article page

Transplantation Research

ISSN: 2047-1440

Contact us